LONDON, June 08, 2017 (GLOBE NEWSWIRE) -- DroneGuarder Inc. (OTCQB:DRNG) is pleased to announce its final phase of development for its first drone prototype.
Over the past months, we have been architecting and design programing the functionality of our first DroneGuarder prototype, which is expected to be completed near the end of June or early July. The functionality work has involved testing and fine tuning real time alerts and streaming video.
Imbedded in the core of our software architecture is artificial intelligence that autonomously makes its own decisions when to activate and patrol the property when it detects a human shaped intruder. The DroneGuarder drone will communicate with a customer’s device app utilizing 4G GSM, as there are 4G coms on board the drone that provides the signal unlimited range. We have also been focused on the integration of DroneGuarder and our software, and how it will integrate into existing alarm systems in a simple plug and play process. Our goal is to have the prototype integrate in a seamless manner to all major manufacturers of alarm systems worldwide.
About DroneGuarder Inc.
DroneGuarder is an early stage security and surveillance company focusing on commercializing a drone enhanced home security system as a turnkey solution. The solution is app-based and includes a drone, infrared camera, and Android mobile app component: Once an alarm has been triggered, the DroneGuarder™ will immediately take off from a wireless charging pad.
Please visit http://www.droneguarder.com to learn about the company, management and products.
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.